Tempus xT CDx
Tempus AI has launched the next-generation sequencing-based xT CDx test. The US Food and Drug Administration-approved test comprises 648 genes and is used to provide solid tumor profiling in cancer patients with solid malignant neoplasms. It detects single- and multi-nucleotide variants, insertions, and deletions and microsatellite instability status from formalin-fixed, paraffin-embedded tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens. The companion diagnostic test is intended to identify patients who may benefit from treatment with certain targeted therapies.